Schonfeld Strategic Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Schonfeld Strategic Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-26,992	Closed	-$707K	–	2871
2022 Q4	$707K	Sell	26,992 -70,782	-72%	-$1.57M	0.01%	1339
2022 Q3	$1.92M	Buy	97,774 +85,063	+669%	+$1.71M	0.02%	882
2022 Q2	$223K	Buy	+12,711	New	+$200K	﹤0.01%	1833
2020 Q2	–	Sell	-4,236	Closed	-$58K	–	1618
2020 Q1	$58K	Buy	+4,236	New	+$50.1K	﹤0.01%	1048
2018 Q2	–	Sell	-11,784	Closed	-$548K	–	1027
2018 Q1	$548K	Buy	+11,784	New	+$431K	0.04%	449
2017 Q2	–	Sell	-5,018	Closed	-$270K	–	819
2017 Q1	$270K	Buy	+5,018	New	+$283K	0.03%	490
2016 Q4	–	Sell	-3,675	Closed	-$228K	–	673
2016 Q3	$228K	Buy	+3,675	New	+$260K	0.04%	344

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Schonfeld Strategic Advisors's KDNY Position: Q1 2023 in Review

Schonfeld Strategic Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2023, closing a stake of 26,992 shares — an estimated $707K sold.

Schonfeld Strategic Advisors first reported a position in KDNY in Q3 2016 and held it in 7 quarters. The position peaked at $1.92M in Q3 2022. 157 funds tracked by Wall St. Rank hold KDNY as of Q1 2023.

Schonfeld Strategic Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Schonfeld Strategic Advisors sold 26,992 Chinook Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $707K.
Schonfeld Strategic Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2016 and held it in 7 quarters.
Schonfeld Strategic Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $1.92M in Q3 2022.
157 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.